Edwards Lifesciences Corporation: stock overview

EWNYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Price

$107.15

November 13, 2026Market cap $62.2B

DCF calculator

What Ploutos Investor adds for Edwards Lifesciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Edwards Lifesciences had revenue of $6.7B over the last 12 months and net income of $1.0B, a net margin of 15.3%. Revenue grew by 6.7% a year on average over the last 5 years. At $107.15 the shares trade at a P/E of 60.9, against a median of 33.2 over the last 5 fiscal years. It holds more cash than debt, by $4.0B. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$62.2B
581M shares
P/E
60.9
Today60.9
Median33.2
Revenue, 12 months
$6.7B
+6.7% a year over 5 years
Net margin
15.3%
2025: 17.7%, above 87% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+10.0% a year over 2 years

  • 202510-K
    Revenue$6.1B
  • 202410-K
    Revenue$5.4B
  • 202310-K
    Revenue$5.0B

Fiscal years in figures

EW's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $45.8B
$62.2B
Enterprise value 
$58.2B
P/E 3-year median: 33.2
60.9
EV / EBIT 
40.4
EV / Revenue 
8.7
P/B 3-year median: 4.8
5.7
FCF yield 3-year median: 1.4%
2.3%
Earnings yield 3-year median: 3.0%
1.6%

Profitability

Gross margin 
78.0%
Operating margin 
21.6%
Net margin 3-year median: 28.0%
15.3%
ROIC 
9.0%
ROIC, 5-year average 
14.6%
ROE 
9.8%

Growth

Revenue, yearly change 
+11.6%
EPS, yearly change 
-73.7%
FCF, yearly change 
+360.5%
Revenue, average a year 
+6.7%
EPS, average a year 
+7.1%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$4.6B
Total debt 
$705M
Of which operating leases 
$106M
Net cash 
$4.0B
Net debt / EBITDA 
-2.5x
Interest cover 
70.6x
Current ratio 
4.60

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
1.44%
Total returned 
1.44%
Shares, yearly change 
-1.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

78.0%

Above 91% of the 161 companies in its industry, and 94% of all.

Operating margin

20.8%

Above 91% of the 186 companies in its industry, and 84% of all.

Net margin

17.7%

Above 87% of the 189 companies in its industry, and 79% of all.

ROE

10.4%

Above 70% of the 174 companies in its industry, and 62% of all.

ROA

7.8%

Above 78% of the 190 companies in its industry, and 82% of all.

Revenue growth

11.6%

Above 62% of the 186 companies in its industry, and 66% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Edwards Lifesciences Corp
CIK
1099800
Exchange
NYSE
Industry (SIC)
3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
581M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Edwards Lifesciences's filings show?

These are Edwards Lifesciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about EW

Didn't find what you were looking for?

Ask us
What is EW's market cap?

Edwards Lifesciences Corporation's market cap is $62.2B, at a price of $107.15 on November 13, 2026 and 581M shares.

What is EW's P/E?

EW's P/E is 60.9, on earnings per share of $1.77 over the last 12 months. The median over the last 5 fiscal years was 33.2.

How much revenue does EW have?

Edwards Lifesciences had revenue of $6.7B over the last 12 months. Over the last 5 years it changed by +6.7% a year on average.

Does EW pay a dividend?

No. Edwards Lifesciences paid no regular dividend over the last 12 months.

Where do the figures come from?

From Edwards Lifesciences Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.